MARKET

BMEA

BMEA

Biomea Fusion, Inc.
NASDAQ
8.01
-0.02
-0.25%
Pre Market: 8.10 +0.09 +1.12% 08:00 11/13 EST
OPEN
8.02
PREV CLOSE
8.03
HIGH
8.18
LOW
7.77
VOLUME
1
TURNOVER
0
52 WEEK HIGH
22.74
52 WEEK LOW
3.610
MARKET CAP
290.27M
P/E (TTM)
-2.0010
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BMEA last week (1104-1108)?
Weekly Report · 2d ago
Weekly Report: what happened at BMEA last week (1028-1101)?
Weekly Report · 11/04 09:24
Short Report: Archer Aviation shorts at seven-week high
TipRanks · 11/03 17:20
BIOMEA FUSION, INC. REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 11/01 20:05
Press Release: Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Dow Jones · 11/01 20:05
Biomea Fusion Is Maintained at Overweight by Piper Sandler
Dow Jones · 10/31 18:34
Piper Sandler Maintains Overweight on Biomea Fusion, Raises Price Target to $19
Benzinga · 10/31 18:24
Biomea Fusion Is Maintained at Buy by EF Hutton
Dow Jones · 10/31 12:51
More
About BMEA
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).

Webull offers Biomea Fusion Inc stock information, including NASDAQ: BMEA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMEA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BMEA stock methods without spending real money on the virtual paper trading platform.